Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intermittent Mupirocin to Prevent Staphylococcal Infection.

Trial Profile

Intermittent Mupirocin to Prevent Staphylococcal Infection.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Aug 2018

At a glance

  • Drugs Mupirocin (Primary) ; Polyethylene glycol
  • Indications Staphylococcal infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jan 2013 Actual end date changed from Mar 2010 to Aug 2012 as reported by ClinicalTrials.gov.
    • 28 Jun 2010 Actual end date added to 1 Mar 2010 as reported by ClinicalTrials.gov.
    • 28 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top